Decrease of B-cells and autoantibodies after low-dose methotrexate

Biomedicine and Pharmacotherapy

Volumn 57, Issue 7, 2003, Pages 278-281

  Böhm, Ingrid ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Immune modulation; Lupus erythematosus; Methotrexate

Indexed keywords

AUTOANTIBODY; METHOTREXATE;

ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS; LYMPHOCYTE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0141783731     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(03)00086-6     Document Type: Article

References (9)

1. Bottomley W.W., Goodfield M.J.D. Methotrexate for the treatment of discoid lupus erythematosus. Br J Dermatol. 133:1995;655-656.
2. Goldstein E., Carey W. Discoid lupus erythematosus: successful treatment with oral methotrexate. Arch Dermatol. 130:1994;938-939.
3. Hashimoto M., Nonaka S., Furuta E., Wada T., Suenaga Y., Yasuda M., Shingu M., Nobunaga M. Methotrexate for steroid-resistant systemic lupus erythematosus. Clin Rheumatol. 13:1994;280-283.
4. Linker-Israeli M., Deans R.J., Wallace D.J., Prehn J., Ozeri-Chen T., Klinenberg J.R. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol. 147:1991;117-123.
5. Martinez-Osuna P., Zwolinska J.B., Sikes D.H., Cory J.G., Silveira L.H., Jara L.J., et al. Lack of immunosuppressive effect of low-dose oral methotrexate on lymphocytes in rheumatoid arthritis. Clin Exp Rheumatol. 11:1993;249-253.
6. Meheus L., van Venrooij W.J., Wiik A., Charles P.J., Tzioufas A.G., Meyer O., et al. Multicenter validation of recombinant, natural and synthetic antigens used in a single multiparameter assay for the detection of specific anti-nuclear autoantibodies in connective tissue disorders. Clin Exp Rheumatol. 17:1999;205-214.
7. Rosenthal G.J., Weigand G.W., Germolec D.R., Blank J.A., Luster M.I. Suppression of B cell function by methotrexate and trimetrexate. Evidence of inhibition of purine biosynthesis as well as a major mechanism of action. J Immunol. 141:1988;410-416.
8. Segal R., Mozes E., Yaron M., Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum. 32:1989;370-377.
9. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25:1982;1271-1277.